Rosen Law Firm Encourages Inovio Investors to Secure Counsel Before Deadline

Investors who purchased Inovio securities between October 2023 and December 2025 may be eligible for compensation.

Mar. 16, 2026 at 2:04am

Got story updates? Submit your updates here. ›

Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025 of the important April 7, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Inovio made false and/or misleading statements about its CELLECTRA device manufacturing and the regulatory prospects for its INO-3107 drug candidate.

Why it matters

This case highlights the importance of investor protections and the role of securities class actions in holding companies accountable for alleged misconduct that impacts shareholders. The outcome could have significant financial implications for affected Inovio investors.

The details

According to the lawsuit, Inovio defendants made false and/or misleading statements about: (1) deficiencies in manufacturing for its CELLECTRA device; (2) the likelihood of Inovio submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024; (3) the eligibility of INO-3107 for FDA accelerated approval or priority review; and (4) the overall regulatory and commercial prospects for INO-3107. The lawsuit claims that when the true details entered the market, investors suffered damages.

  • The class period is from October 10, 2023 to December 26, 2025.
  • The lead plaintiff deadline is April 7, 2026.

The players

Rosen Law Firm

A global investor rights law firm representing investors in securities class actions.

Inovio Pharmaceuticals, Inc.

A biopharmaceutical company developing DNA medicines for infectious diseases, cancer, and other diseases.

Got photos? Submit your photos here. ›

What they’re saying

“To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.”

— Phillip Kim, Attorney, Rosen Law Firm (Globe Newswire)

What’s next

The judge will decide on the lead plaintiff by April 7, 2026.

The takeaway

This case underscores the importance of transparency and accuracy in public company disclosures, as well as the role of securities class actions in protecting investor rights and seeking compensation for alleged corporate misconduct.